Abstract C050: Allele-specific expression analysis identifies novel dysregulated genes in high-risk prostate tumors from African-American men

Abstract

Abstract African-American (AA) patients are twice as likely to die from prostate cancer (PCa) compared to European American (EA) patients. Racism, socioeconomic status, access to healthcare, and tumor biology have been attributed to this mortality gap. Tumor biology has not been fully characterized in AA patients, particularly the landscape of gene-regulatory alterations and how they may contribute to tumor aggressiveness. We use allele specific expression (ASE) analysis, which detects genes showing imbalanced expression of alleles often due to altered gene regulation on one allele, to comprehensively identify dysregulated genes in high-risk PCa tumors from AA patients. We develop a framework for identifying candidate cancer genes by integrating ASE data, clinical data, and epigenetics. Our approach identifies genes that recurrently undergo ASE across AA patient tumors. Further, we describe genes that more frequently undergo ASE in AA patient tumors compared to EA patient tumors, some of which are implicated in hormone therapy resistance, aggressive disease, and worse disease-free survival. Our work demonstrates the potential for ASE to uncover dysregulated genes that may not have been identified through RNAseq alone. Ultimately, this work increases our understanding of the effects of regulatory alterations in tumors and how they may contribute to disparities in PCa. Citation Format: Margaret Tsui, Kevin Hu, Hanbing Song, Franklin W. Huang. Allele-specific expression analysis identifies novel dysregulated genes in high-risk prostate tumors from African-American men [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C050.